SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Edesa Biotech
Ownership Disclosure
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in Edesa Biotech, Inc.
Summary
- Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- The Reporting Persons collectively beneficially own 855,583 Common Shares of Edesa Biotech, Inc., representing 9.99% of the class outstanding.
- This ownership includes 230,583 shares that can be acquired within sixty days through the exercise of convertible securities.
- Nantahala Capital Management, LLC is classified as an investment adviser, and Messrs. Harkey and Mack are control persons.
- The shares are held with shared voting power and shared dispositive power among the Reporting Persons.
- BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, has the right to receive dividends or proceeds from the sale of more than five percent of the beneficially owned shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by an institutional investor like Nantahala Capital Management can indicate a vote of confidence in Edesa Biotech's prospects, even if it's a passive filing.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional ownership disclosures, particularly from investment managers like Nantahala Capital, can signal increased investor interest or confidence in a company within the biotech sector. A nearly 10% stake suggests a significant position.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and attracting further institutional interest.
- Company Management: Awareness of a large institutional holder may influence strategic decisions or engagement with the investor.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires filing of this statement |
| 02/13/2026 | Filing date of the Schedule 13G Amendment No. 1 |
Keywords
Edesa Biotech, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotech, Common Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.